Boris Duchemann
Bobigny, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 93 publications
Retraction: Randomized Trial of Relevance of Time-of-Day of Immunochemotherapy for Progression-free and Overall Survival in Patients With Non-small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2026
End-of-life management and causes of death in ALK-positive non-small cell lung cancer in France: a multicentric analysis.
Journal: Translational lung cancer research
Published: March 27, 2026
Timing of Immunotherapy in Practice: Feasibility and Impact of Morning Checkpoint Inhibitor Administration.
Journal: JCO oncology practice
Published: December 15, 2025
Organising pneumonia following amivantamab treatment: a case report.
Journal: Respiratory medicine and research
Published: September 09, 2025
Tracheobronchial Replacement Using Cryopreserved Aortic Allografts: Results in 50 Patients (TRITON-01 Registry).
Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
Published: August 26, 2025
Perioperative chemo immunotherapy in non-small-cell lung cancer: what can we learn from the long-term results of NADIM?
Journal: Translational lung cancer research
Published: July 30, 2025
Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial.
Journal: Nature medicine
Published: July 22, 2025
Recommendations on the prevention and management of radiation-induced lung injury from the Association francophone pour les soins oncologiques de support and the Société française de radiothérapie oncologique
Journal: Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Published: May 19, 2025
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 12, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 19, 2025
Last Updated: 09/26/2026